Side by side
IGF-1 LR3 vs Tesamorelin
Both are discussed for muscle & performance. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| IGF-1 LR3 | Tesamorelin | |
|---|---|---|
| What it is | A modified insulin-like growth factor engineered to last far longer in the body than the natural hormone. It can cause hypoglycaemia, which makes it the most acutely dangerous compound on this site. | A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials. |
| EvidenceHow much human evidence exists, not how well it works. | Preclinical | Approved for another indication |
| Regulatory statusReviewed 2026-08-16 | Not approved for human use in any jurisdiction, and never studied in a human trial. Recombinant IGF-1 itself (mecasermin) is approved for severe primary IGF-1 deficiency, and its labelling carries an explicit hypoglycaemia warning. That warning is the closest thing to clinical safety information this class has. | Approved by the FDA as a prescription medicine for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for body composition, athletic performance or anti-ageing use, and material sold as a research chemical is not the approved product. |
| Routes | Subcutaneous, Intramuscular | Subcutaneous |
| Half-life | 24 hours | 0.4 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $32.50/mg | $2.35/mg |
| Median per mg | $79.00/mg | $7.00/mg |
| Vendors with a price | 32 | 49 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. Larger proteins are less forgiving of temperature swings than short peptides. | Refrigerated at 2–8 °C. The approved product is intended for use shortly after reconstitution rather than stored for weeks. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.